Alembic API-III Inspection Report 2025

  Published 1 year ago

Alembic Pharmaceuticals' API-III facility inspection occurred March 17-21, 2025. The company produces globally approved generic drugs with USFDA certified research and manufacturing.

  • Inspection timeframe: 5-day review of operations and compliance standards.
  • Vertically integrated R&D and manufacturing ensure product quality and regulatory adherence.
  • Facility approved by USFDA and other global regulators for pharmaceutical production.

You might like these

IndusInd Bank Upgraded to Buy by Nomura, Eyes Recovery

Vodafone Idea AGR Relief Sparks Hope

Torrent Pharma Gains on Citi Upgrade

India & Kyrgyzstan Strengthen Investment Ties

SEBI Opens Institutional Commodity Markets

India's Rice Support Price Rises Slightly

DoT Shares Fraud Risk Indicator for Cyber Protection

News that matters the most ⚡